Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11544047 | 0.95 | LTA4H (0.46) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL10740412 | 0.91 | TSHR (0.48) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL6277239 | 0.83 | L3MBTL1 (0.49) | MEN1KMT2APTPN1NPC1MAPT | |
| SCHEMBL9451333 | 0.81 | CA1 (0.55) | MEN1KMT2AMAOBKCNH2CA1 | |
| SCHEMBL16964735 | 0.81 | CA12 (0.47) | MEN1KMT2APTPN1CA1CA2 | |
| SCHEMBL1751861 | 0.81 | KDM4E (0.45) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL11445546 | 0.81 | CYP1A2 (0.50) | DRD2DRD4DRD3CYP1A2CYP2C19 | |
| SCHEMBL3947128 | 0.81 | LTA4H (0.50) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL4469836 | 0.81 | APP (0.42) | PTPN1CA1CA2CA9NPC1 | |
| SCHEMBL7976554 | 0.81 | KCNA3 (0.52) | MEN1KMT2AMAPTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | RECREO PHARMACEUTICALS LLC (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3836919-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | Recreo Pharmaceuticals Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2020037155-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020037155-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | RECREO PHARMACEUTICALS LLC (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | disclosed |
| WO-2005048916-A2 | TETRAHYDROSPIRO-BETA-CARBOLINE-1,3 '-PYRROLIDINE DERIVATIVES AND THEIR USE IN GHSR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371429-B2 | Antibiotic resistance-modifying tricyclic heteroaryl compounds and uses thereof | CBR3, CBR1, CYP2B6 | MEN1 1968/4885KMT2A 1544/4885DRD2 159/4885 |
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | GHSR, GHRHR, PRLHR | MEN1 150/4885KMT2A 2414/4885DRD2 175/4885 |
| US-20210163479-A1 | 1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOLE DERIVATIVE COMPOUNDS AND USES THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNA1, FOXM1 | MEN1 1942/4885KMT2A 1984/4885DRD2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.